


Eosinophilic Disorders

3,478

Patients seen at the Cincinnati Center for Eosinophilic Disorders from 2009—June 2022



Patients who participate in research at the Cincinnati Center for Eosinophilic Disorders



Patients travel to Cincinnati Children's for care for eosinophilic disorders from 50 states and 13 countries



Cincinnati Children's is ranked #1 in Gastroenterology & GI Surgery and #3 in the nation among Honor Roll hospitals.

Cincinnati Children's Hospital Medical Center is a worldwide leader in the diagnosis, treatment and research of eosinophilic disorders. The Cincinnati Center for Eosinophilic Disorders, established in 2001, was the first of its kind to focus solely on these complex medical problems in children and adults. Today, patients with eosinophilic disorders travel from all over the country and different parts of the world to receive comprehensive care at Cincinnati Children's. Our specialists engage in extensive research efforts to enhance the understanding of these disorders, fuel the development of novel therapies and find a cure.

HOW WE'RE DIFFERENT

Our evidence-based approach integrates clinical expertise, research and education across disciplines. This allows us to treat eosinophilic disorders effectively, as well as manage common comorbidities of eosinophilic GI disease, including connective tissue disease, eczema, asthma, heart disease, food allergies, behavioral problems and life-adjustment issues.

- Our multidisciplinary team includes three gastroenterologists, a pathologist, three allergists, nutritionists and dedicated nursing staff. Geneticists, psychologists and others contribute their expertise as needed. These specialists work collaboratively to develop a unified plan of care tailored to the needs of each patient and family.
- We surround patients and families with additional support through educational seminars, webinars, camps and support groups, often coordinating our efforts with patient advocacy groups and foundations.
- Cincinnati Children's serves as a major education center for medical professionals who want to receive training in the care and research of eosinophilic disorders. Our faculty publishes an article on eosinophilic disorders nearly every two weeks.
- Every patient is given the opportunity to participate in research at the center, with more than 50 percent currently actively participating.

CONDITIONS TREATED

- Eosinophilia
- Eosinophilic colitis
- Eosinophilic duodenitis
- Eosinophilic esophagitis
- Eosinophilic gastritis
- Eosinophilic gastroenteritis
- Eosinophilic granulomatosis with polyangiitis
- Hypereosinophilic syndrome

TREATMENT TEAM

Pediatric Gastroenterology

Philip E. Putnam, MD

Medical Director

Scott Bolton, MD

Vincent A. Mukkada, MD

Adult Gastroenterology

Vidhya Kunnathur, MD

*University of Cincinnati
College of Medicine*

Pathology

Margaret H. Collins, MD

Psychology

Nicole E. Zahka, PhD

Allergy / Immunology

Marc E. Rothenberg, MD, PhD

Director

J. Pablo Abonia, MD

Erinn Kellner, MD

Justin Schwartz, MD, PhD

Nursing

Kelly Hensley, RMA

Joan Higby, RN, BSN

Chelsey Lockwood, BSN, RN, CPN

Candice S. Moore, BSN, RN, CPN

Elizabeth Netzel, MSN, RN, CPN

Nutrition

Alison Cassin, MS, RD, LD

Meghan McNeill, MS, RD, LD

Clinical Research Team

Kara Kliewer, PhD, RD

Clinical Research Manager

Emily Anno, BS

Heather Foote

Pratibha Kentur, BDS, MDS

Cristin Murray-Petzold, BS

Savannah Neal, BS

Regina Yearout, BS

Julia Zupan, BA

Program Manager

Julie Daisey, MS

www.cincinnatichildrens.org

TREATMENT APPROACH

We conduct an initial, multi-day assessment at Cincinnati Children's that includes diagnostic tests, clinic visits with a gastroenterologist and other specialists, a nutrition evaluation and extensive education. At the end of the week, our team meets with the patient-family to discuss findings and treatment recommendations, which can include elimination diets, elemental diets, medication or novel therapies.

If patient-families choose to receive long-term care at Cincinnati Children's, they typically return twice a year, when we evaluate their progress and make adjustments to the treatment plan as needed. Our team offers traditional gastrointestinal endoscopy performed under anesthesia in a procedure center or operating room, as well as transnasal endoscopy services, which do not involve anesthesia and are performed in an outpatient clinic. Telemedicine may be available for established patients (Ohio residents).

CLINICAL RESEARCH TO IMPROVE PATIENT CARE

Grants, foundation funding and philanthropy are used to carry out life-impacting basic, translational and clinical research focused on deciphering, treating and curing eosinophilic disorders. Our team pioneered evaluating the effectiveness of anti-interleukins (ILs, such as mepolizumab and dupilumab), biological agents and topical glucocorticoids in the management of eosinophilic disease, contributing to recent FDA approvals (e.g., Dupixent®). Among our current research efforts are studies investigating novel genetic diagnosis and predictive medicine; identifying compounds that block eosinophil production; stratifying patients with eosinophilic disorders by subgroups; and understanding the mechanisms of drugs, such as anti-IL-13 therapeutics. Current research protocols include testing biological therapies (anti-IL-4Rα, anti-IL-5, anti-IL-5Rα, anti-IL-13 and anti-Siglec-8).

With the support of a five-year, \$7.89-million grant from the National Institutes of Health, Cincinnati Children's leads a consortium of organizations with a common goal to improve the lives of individuals with eosinophilic gastrointestinal disorders through innovative research, clinical expertise and education via collaborations between scientists, health care providers, patients and professional organizations. This Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is a collaboration of clinician-investigators, translational scientists, physicians, patients, families and patient advocacy groups and is part of the Rare Diseases Clinical Research Network (RDCRN). Marc E. Rothenberg, MD, PhD, director of the Cincinnati Center for Eosinophilic Disorders, is the principal investigator and director for this research, which involves researchers from over 18 hospitals and universities and the National Institutes of Health.

BY THE NUMBERS



Publications on eosinophilic disorders in Fiscal Year 2022

15

Current basic, clinical and translational studies to better understand the causes of eosinophilic disorders, identify more effective diagnostic tests and treatments and develop a cure for the disease

For urgent issues, or to speak with the specialist on call 24/7, call the Physician Priority Link® at 1-888-987-7997. For international inquiries, call +1-513-636-3100 or email international@cchmc.org.